Charles Schwab Investment Management Inc Eliem Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 17,128 shares of ELYM stock, worth $87,524. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,128Holding current value
$87,524% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding ELYM
# of Institutions
47Shares Held
49.9MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$161 Million3.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.9MShares$20 Million0.91% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.26MShares$16.7 Million11.93% of portfolio
-
Janus Henderson Group PLC London, X03.25MShares$16.6 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA2.6MShares$13.3 Million1.03% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $136M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...